Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q1 2024 Earnings Call Transcript

Jack Phillips: Sure. Thank you. In summary, we’ve made very good progress in several areas in the quarter. I’m really proud of our team and what we’ve accomplished as highlighting some of those. As David mentioned we added 12 new rapid AST systems in the quarter in conjunction with our partner BD. We executed contract extensions with several strategic U.S. customers, which will secure approximately 70% of Accelerate customer base to longer term contracts for Wave. We successfully submitted a 510(k) through the FDA for Arc. And we — as I mentioned prior, we received confirmation already and our submission is currently under review. And then the Wave program, we continue to make great progress. The preclinical trial remains underway.

We’re targeting still to begin clinical trials in late quarter two and we’ve also began development of gram-positive — the gram-positive PBC menu. So, a lot of good things happening there on the Wave front. And then finally as David highlighted we continue to implement initiatives to improve our cash burn and extend our runway. So, that’s going very well as well. I want to say thank you very much for tuning into our Q1 earnings call. We appreciate your interest in accelerate and I wish you a great day.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.